PHILADELPHIA--(BUSINESS WIRE)--iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver ...
PHILADELPHIA--(BUSINESS WIRE)--iECURE, a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver ...
The European Commission (EC) granted orphan designation to iECURE's lead product GTP-506 to treat Ornithine Transcarbamylase (OTC) deficiency. OTC deficiency is a type of urea cycle disorder. It is a ...
The FDA has granted orphan drug designation to Iecure Inc.'s lead product candidate GTP-506, an investigational product for the treatment of ornithine transcarbamylase (OTC) deficiency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback